

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A method for the selective enhancement of the expression of a Stra6 protein in a tumor cell characterized by aberrant Wnt signaling comprising treating said tumor cell with an effective amount of a retinoid.
2. (Canceled)
3. (Currently Amended) The method of claim 1, wherein said Stra6 protein is a cell surface protein.
4. (Currently Amended) The method of claim 1 wherein said Stra6 protein is over-expressed in tumor cells relative to ~~corresponding~~ normal cells of the same tissue type as the tumor cells.
- 5-7. (Canceled)
8. (Original) The method of claim 1 wherein said retinoid is a retinoic acid.
9. (Original) The method of claim 1 wherein said tumor is a human cancer.
10. (previously presented) The method of claim 9 wherein said human cancer is colon cancer, or breast cancer.
- 11-66. (Cancelled)
67. (Currently Amended) A method for the selective enhancement of expression of a Stra6 protein in a tumor cell characterized by aberrant Wnt signaling comprising treating said

tumor cell with an effective amount of a retinoid, wherein said Stra6 protein is characterized by synergistic enhancement of its expression by a combination of Wnt-1 and said retinoid.

68. (Currently Amended) The method of claim 67, wherein said Stra6 protein is a cell surface protein.

69. (Currently Amended) The method of claim 67, wherein said Stra6 protein is overexpressed in tumor cells relative to ~~corresponding~~ normal cells of the same tissue type as the tumor cells.

70. (Canceled)

71. (previously presented) The method of claim 67, wherein said retinoid is a retinoic acid.

72. (previously presented) The method of claim 67, wherein said tumor is a human cancer.

73. (previously presented) The method of claim 72, wherein said human cancer is colon cancer or breast cancer.

74. (Currently Amended) A method for selective enhancement of the expression of a Stra6 protein in a tumor cell characterized by aberrant Wnt signaling of a member of Wnt signaling pathway selected from the group consisting of Wnt gene family, APC, catenin, frizzled receptors, dishevelled protein, glycogen synthase kinase-3 β , transcription factor TCF/LEF-1, nodal related 3 gene, Xnr3, the homeobox genes, engrailed, goosecoid, twin (Xtwn), siamois, c-myc and the WISP genes, comprising treating said tumor cell with an effective amount of a retinoid.

75. (Currently Amended) The method of claim 74, wherein the Stra6 protein is a cell surface protein.

76. (Currently Amended) The method of claim 74, wherein said Stra6 protein is overexpressed in tumor cells relative to ~~corresponding~~ normal cells of the same tissue type as the tumor cells.

77. (Canceled)

78. (previously presented) The method of claim 74, wherein the retinoid is retinoic acid.

79. (previously presented) The method of claim 74, wherein the tumor is human cancer.

80. (previously presented) The method of claim 79, wherein the human cancer is colon cancer or breast cancer.